Table 1

Clinical and laboratory features of patients before and after TCZ

M0 (previous treatment)M6M12M0 (previous treatment)M6M12
TCZ treatmentNSAID, steroids, methotrexate, hydroxychloroquine, etanercept, adalimumabTCZ, steroids (low dose at 5 mg/day), hydroxycholoroquineNSAID, steroids, methotrexate, hydroxychloroquine, mycophenolate mofetil, etanerceptTCZ, steroids (low dose at 5 mg/day), hydroxychloroquin, methotrexate
Age (years)151617151516
Joint manifestation (cJADAS)*20001410
Raynaud's phenomenon++++++
 Hb (g/L)129115119125116135
 WCC (g/L)
 Lymphocytes (g/L)2.361.351.151.792.31.51
 CRP (<5 mg/L)36.2<0.2<0.218.6<0.2<0.2
 ASAT (<40 U/L)312428101145<40
 ALAT (<40 U/L)13172588326<40
 CK (<200 U/L)12929880
 dsDNA Ab RIA (Farr assay >7 UI/mL)3085>977.47.17
 Anti-SSA 60 kDa>2>23.7
 Cryoglobulinaemia+ (type III)+ (type III)
  • *The clinical (3-variable) cJADAS: inactive disease <1, low disease activity <2.5, moderate disease activity 2.51–8.5, high disease activity >8.5.

  • Ab, antibody; ALAT, alanine aminotransferase; ANA, antinuclear antibody; ASAT, aspartate aminotransferase; cJADAS,clinical (3-variable) Juvenile Arthritis Disease Activity Score; CK, creatine kinase; CRP, C reactive protein, ds, double-stranded; Hb, haemoglobin; NSAID, non-steroidal anti-inflammatory drugs; RIA, radioimmunoassay; SSA, anti-Sjögren's-syndrome-related antigen A; TCZ, tocilizumab; Anti-U1 RNP, Anti-U1 small nuclear ribonucleoprotein; WCC, white cell count.